Intuitive Surgical Set to Report Revenues of $1.02 Billion in Q4 Earnings Report

Trending News 🌥️

Intuitive Surgical ($NASDAQ:ISRG) is a global leader in the development of minimally invasive robotic-assisted surgical systems. The company’s robotic-assisted systems are used in a wide range of surgical procedures, from cardiothoracic and general surgery to gynecological and urological surgery. Intuitive Surgical’s systems are designed to help surgeons operate with greater precision, accuracy, and control while minimizing patient trauma, post-operative pain and recovery time. On Tuesday, January 24th, Intuitive Surgical will report its Q4 earnings report after the stock market closes. Additionally, analysts are expecting the company’s earnings per share (EPS) to be $1.25 for the quarter. The company’s success is largely attributed to their robotics-assisted systems which have become increasingly popular in the healthcare industry as surgeons look for ways to reduce patient trauma and recovery time.

In addition, Intuitive Surgical has also been investing heavily in research and development, which has resulted in a steady stream of new products being released over the past few years. Investors will be keeping a close eye on the earnings report to get an update on their financial performance and to see if their investments will pay off in the long run.

Stock Price

On Monday, the stock opened at $256.8 and closed at $256.0, which was a 0.3% decrease from its previous closing price of 256.8. The company has been under scrutiny recently for its robotic surgical system, which has been linked to several deaths. This has caused many investors to be wary of the company and has caused their stock price to go down. The company’s revenue is expected to be driven by growth in its international market, with strong sales in Europe and Asia. Intuitive Surgical’s products have been well received in the medical community, due to their ability to reduce patient trauma and shorten hospital stays.

Investors will be closely watching the fourth quarter earnings report for any signs of further revenue growth and how the company plans to address the recent issues that have been raised. The company has also been investing in research and development in order to improve its products. It remains to be seen how these investments will impact the company’s revenue in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Intuitive Surgical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Intuitive Surgical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Intuitive Surgical. More…

Key Ratios Snapshot

Some of the financial key ratios for Intuitive Surgical are shown below. More…

VI Analysis

VI App’s analysis of INTUITIVE SURGICAL has revealed it to be a medium risk investment from both a financial and business perspective. This easy to access rating provides a risk overview of the company’s fundamentals, offering insights into its long term potential. In terms of financial risk, VI App’s analysis has identified three risk warnings in the income sheet, cashflow statement and non-financial aspects. These warnings can be used to help guide investors in making informed decisions about their investments. VI App is designed to make the assessment of a company’s risk easier and more accessible. It simplifies the process by providing an overview of the company’s fundamental risk factors, saving investors time and money. It also provides helpful insights into the long term potential of a company. In addition to its risk rating, VI App also offers comprehensive data on every aspect of the company, including its financials, operations, industry trends and competitive landscape. This information helps investors make better decisions when it comes to investing in INTUITIVE SURGICAL. Overall, VI App’s analysis of INTUITIVE SURGICAL is a useful tool for investors looking for information about the company’s fundamentals and long term potential. By providing an overview of the company’s financial and business risk factors, it enables investors to make more informed decisions about their investments. More…

VI Peers

The company’s da Vinci surgical system consists of a surgeon’s console, a patient-side cart and a vision system. The company’s competitors in the robotic surgery market include Stryker Corp, Medtronic PLC, Becton, Dickinson and Co.

– Stryker Corp ($NYSE:SYK)

With a market capitalization of $84.98 billion as of 2022, Stryker Corporation is one of the world’s leading medical technology companies. Headquartered in Kalamazoo, Michigan, the company offers a broad range of products and services in orthopedics, medical and surgical, and neurotechnology and spine that help improve patient care and quality of life. The company’s products include implants used in hip, knee and shoulder replacements, as well as instrumentation and software used in operating rooms and for patient rehabilitation. In addition, Stryker offers a wide range of products and services for minimally invasive surgery, including robotic-assisted surgery systems. The company’s return on equity was 10.79% as of 2022.

– Medtronic PLC ($NYSE:MDT)

Medtronic PLC is a medical technology company that develops and produces a variety of medical devices and software products. The company has a market capitalization of 112.31 billion as of 2022 and a return on equity of 7.49%. Medtronic PLC’s products are used in a wide range of medical procedures, including cardiovascular, neurological, and orthopedic procedures. The company’s products are sold in over 150 countries around the world.

– Becton, Dickinson and Co ($NYSE:BDX)

Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, laboratory equipment, and diagnostic products. The company has a market cap of 64.37B as of 2022 and a return on equity of 6.42%. The company’s products are used in a variety of medical procedures, including blood transfusions, IV start kits, and diabetes care.

Summary

Intuitive Surgical Inc., a manufacturer of robotic-assisted surgical systems, is set to report fourth quarter revenues of $1.02 billion in its upcoming earnings report. The company has seen mostly negative media coverage in recent months, making investors cautious. Despite these concerns, the company has a strong market presence and its products are widely used in healthcare facilities worldwide. As such, it is worth considering for investors looking for long-term investment opportunities.